Systems for controlled drug delivery.

Abstract

Medicinal Research ReviewsVolume 1, Issue 4 p. 373-386 Article Systems for controlled drug delivery Alejandro Zaffaroni, Alejandro Zaffaroni ALZA Corporation, 950 Page Mill Road, Palo Alto, California 94304 Alefandro Zaffaroni is noted for his contributions to steriod biochemistry and for his pioneering accomplishments in the field of controlled drug delivery. A native of Montevideo, Uruguay, Dr. Zaffaroni received his Ph.D. from the University of Rochester. At Syntex Corporation, which he joined in 1951, he became Executive Vice President, President of Syntex Laboratories, and President of Syntex Research. in 1968, he left Syntex and established ALZA Corporation to develop more physiologic approaches to drug therapy. Under his direction, ALZA Corporation to develop more physiologic approaches to drug therapy. Under his direction, ALZA has developed innovative systems-for routine use via the oral, injectable, transdermal, intravenous, and topical routed-that deliver drugs at precisely controlled rates over prolonged durations following one application. More recently, Dr. Zaffaroni founded and became Chairman of the Board of DNAX, Ltd., a privately funded corporation in which ALZA holds a minority interest. The new company will develop macromolecular products for medicine by combining the technologies of genetic engineering, immurobiology, and advanced drug delivery systems.Search for more papers by this author Alejandro Zaffaroni, Alejandro Zaffaroni ALZA Corporation, 950 Page Mill Road, Palo Alto, California 94304 Alefandro Zaffaroni is noted for his contributions to steriod biochemistry and for his pioneering accomplishments in the field of controlled drug delivery. A native of Montevideo, Uruguay, Dr. Zaffaroni received his Ph.D. from the University of Rochester. At Syntex Corporation, which he joined in 1951, he became Executive Vice President, President of Syntex Laboratories, and President of Syntex Research. in 1968, he left Syntex and established ALZA Corporation to develop more physiologic approaches to drug therapy. Under his direction, ALZA Corporation to develop more physiologic approaches to drug therapy. Under his direction, ALZA has developed innovative systems-for routine use via the oral, injectable, transdermal, intravenous, and topical routed-that deliver drugs at precisely controlled rates over prolonged durations following one application. More recently, Dr. Zaffaroni founded and became Chairman of the Board of DNAX, Ltd., a privately funded corporation in which ALZA holds a minority interest. The new company will develop macromolecular products for medicine by combining the technologies of genetic engineering, immurobiology, and advanced drug delivery systems.Search for more papers by this author First published: Winter 1981 https://doi.org/10.1002/med.2610010404Citations: 14 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume1, Issue4Winter 1981Pages 373-386 RelatedInformation